A Phase IIa Study With Escalating Dose of MS1819-SD

Inclusion Criteria: 1. Signed and dated informed consent form, 2. Age \>18 years, 3. Male or female, 4. Body weight within the range \[50-100 Kg\] for males or \[40-90 Kg\] for females, 5. Distal pancreatectomy for any disorder (e.g. acute pancreatitis or its complications, CP or its complications, pancreatic endocrine or exocrine cancer, or others) and/or CP of any etiology (e.g. alcohol, genetics, hypercalcemia, or others) of grade 2 or higher (Cambridge classification), 6. Faecal pancreatic elastase-1 \<100 μg/g of stools at screening or within one month of the screening visit, 7. CFA measurement ≤ 75% at washout 8. Female patients must be post-menopausal (defined as at least 12 months post cessation of menses), surgically sterile or, if of childbearing potential, using a reliable method of contraception during the study. 9. Being considered as reliable and capable of adhering to the protocol, according to the judgment of the investigator. Exclusion Criteria: 1. Cystic fibrosis, 2. Total or partial gastrectomy, 3. Cephalic or total duodenopancreatectomy, 4. Documented fibrosing colonopathy, 5. Any small bowel disease possibly responsible for malabsorption, including small intestinal bacterial overgrowth, celiac disease, small bowel resection ≥1 meter length, etc., 6. Acute pancreatitis or exacerbation of CP ≤3 months, 7. Pancreatectomy for exocrine or endocrine cancer ≤1 year, 8. Metastatic or locally recurrent exocrine pancreatic cancer, 9. Known hypersensitivity or other severe reaction to any ingredient of the investigational medicinal product, 10. Bilirubin \>3 times ULN (upper limit normal),